Search Result

Pathways Recommended:	Membrane Transporter/Ion Channel Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

CHO cell membranes

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (3) Adenosine Receptor (3) Adrenergic Receptor (1) Apoptosis (1) Autophagy (1) Biochemical Assay Reagents (1) Bradykinin Receptor (2) Calcium Channel (2) CCR (1) CRFR (1) Cytochrome P450 (1) Dopamine Receptor (2) Drug Derivative (1) Drug Intermediate (1) GPR88 (1) HIV (1) Kisspeptin Receptor (1) Neurokinin Receptor (1) Opioid Receptor (5) Prostaglandin Receptor (1) Reference Standards (2) Sigma Receptor (2) Transmembrane Glycoprotein (1) Urotensin Receptor (4)
By Research Areas:	Cancer (4) Cardiovascular Disease (7) Endocrinology (3) Infection (1) Inflammation/Immunology (3) Metabolic Disease (2) Neurological Disease (17)
Click Chemistry:	Azide (1)
Oligonucleotides:	Adenosine (1) Nucleoside Analogs (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Click Chemistry

Oligonucleotides

Targets Recommended: Choline Kinase Programmed Cell Death 4 (PDCD4) Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor BCL6 Tim3 VISTA BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W588725A

N3-Cho bromide 1 Publications Verification Azido-CHOline bromide	Biochemical Assay Reagents	Others
N3-Cho (Azido-choline) bromide is a click chemistry reagent containing an azide group that can be used in the synthesis of cell membrane structures .

HY-15039

SSR240612	Bradykinin Receptor	Metabolic Disease Inflammation/Immunology Endocrinology
SSR240612 is a potent, and orally active specific non-peptide bradykinin B1 receptor antagonist, with K_is of 0.48 nM and 0.73 nM for B1 kinin receptors of human fibroblast MRC5 and HEK cells expressing human B1 receptors, 481 nM and 358 nM for B2 receptors of guinea pig ileum membranes and CHO cells expressing human B1 receptor, respectively.

HY-167856

RTI-122	GPR88	Neurological Disease
RTI-122 is a selective, blood-brain barrier-permeable GPR88 agonist (cAMP EC₅₀=11 nM), with EC₅₀ values of 11.5 nM and 155 nM for human and mouse GPR88, respectively ([ ³⁵S]GTPγS assay). By activating the GPR88 receptor to regulate the cAMP signaling pathway and G protein activity, RTI-122 significantly attenuates Binge-like drinking, reduces alcohol intake, and decreases alcohol-seeking motivation. RTI-122 blocks the reinstatement of alcohol-seeking behavior without affecting water or sucrose intake. RTI-122 exhibits metabolic stability in mice (T_1/2=5.8 h) and can be used to investigate alcohol use disorder .

HY-112624K

Dextran T5 (MW 5,000) Dextran 5; Dextran D5; Dextran T5(MW 4500-5500)	Apoptosis Autophagy	Others
Dextran T5 (MW 5,000) is a sulfated polysaccharide anti-apoptotic and autophagic agent. Dextran T5 (MW 5,000) has sulfated groups and interacts with cell membranes by mimicking endogenous glycosaminoglycans, inhibiting the mitochondrial apoptotic pathway and delaying DNA fragmentation to exert anti-apoptotic activity. Dextran T5 (MW 5,000) also promotes the conversion of LC3-I to LC3-II and the formation of autophagosomes to activate the autophagic pathway. Dextran T5 (MW 5,000) can prolong the survival cycle of CHO cells and increase the production of recombinant erythropoietin (EPO). The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong drug half-life, increase local concentration and reduce immune clearance activity. The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong the half-life of drugs, increase local concentrations, and reduce the activity of immune clearance .

HY-10655

Palosuran 4 Publications Verification ACT-058362	Urotensin Receptor	Cardiovascular Disease
Palosuran (ACT-058362) is a potent, selective, and orally active antagonist of urotensin II receptor, with an IC₅₀ of 3.6 nM for CHO cell membranes expressing human recombinant receptors. Palosuran can improves pancreatic and renal function in diabetic rats .

HY-107691

GR 159897	Neurokinin Receptor	Neurological Disease Endocrinology Cancer
GR 159897 is a highly potent, selective, competitive, brain-penetrated non-peptide neurokinin 2 (NK₂) receptor antagonist. GR 159897 has little or no affinity for NK₁ and NK₃ receptors. GR 159897 inhibits binding of [ ³H]GR100679 to human NK₂ (hNK₂)-CHO cells and rat colon membranes with pK_is of 9.51 and 10, respectively. Antagonizes bronchoconstriction. Anxiolytic-like and anti-tumor effects .

HY-103428

LE 300 2 Publications Verification	Dopamine Receptor 5-HT Receptor	Neurological Disease
LE 300 is a potent and selective dopamine D1-like receptor antagonist with K_is of 1.9 nM and 7.5 nM in CHO cell membranes expressing human dopamine D1 and D5 receptors, respectively. LE 300 is an antagonist of the 5-HT_2A receptor with a pA2 of 8.32 in a rat tail artery assay .

HY-107401

Ancriviroc SCH-351125	HIV CCR Calcium Channel	Infection
Ancriviroc (SCH-351125) is an orally active CCR5 antagonist with an IC₅₀ value of 13 nM against hCCR5. Ancriviroc specifically binds to hCCR5, blocks ligand-induced signal transduction, calcium influx, GTPγS binding, chemotaxis, ligand binding, and HIV-1 entry, induces conformational changes in CCR5, and inhibits infection and replication of R5-tropic HIV-1 .

HY-152656

2-Hydrazinyl-adenosine	Drug Intermediate Adenosine Receptor	Neurological Disease
2-Hydrazinyl-adenosine is a synthetic intermediate. Derivatives of 2-Hydrazinyl-adenosine act as A_2A adenosine receptor agonists. 2-Hydrazinyl-adenosine is used in the research of neurodegenerative diseases .

HY-12709A

ARC 239 dihydrochloride 1 Publications Verification	Adrenergic Receptor	Cardiovascular Disease Inflammation/Immunology
ARC 239 dihydrochloride is a selective α2B/2C adrenoceptor antagonist (pK_d values are 5.95, 7.41 and 7.56 at α2A, α2B, and α2C receptors respectively). ARC 239 dihydrochloride binds to CHO cell membranes expressing human recombinant a2A-, a2B- or a2C-adrenoceptor subtypes with pK_is of 5.6, 8.4, and 7.08, respectively .

HY-10655A

Palosuran hydrochloride 4 Publications Verification ACT-058362 hydrochloride	Urotensin Receptor	Cardiovascular Disease
Palosuran hydrochloride (ACT-058362 hydrochloride) is a potent, selective, and orally active antagonist of urotensin II receptor, with an IC₅₀ of 3.6 nM for CHO cell membranes expressing human recombinant receptors. Palosuran hydrochloride can improves pancreatic and renal function in diabetic rats .

HY-10655AR

Palosuran hydrochloride (Standard) ACT-058362 hydrochloride (Standard)	Reference Standards Urotensin Receptor	Cardiovascular Disease
Palosuran (hydrochloride) (Standard) is the analytical standard of Palosuran (hydrochloride). This product is intended for research and analytical applications. Palosuran hydrochloride (ACT-058362 hydrochloride) is a potent, selective, and orally active antagonist of urotensin II receptor, with an IC50 of 3.6 nM for CHO cell membranes expressing human recombinant receptors. Palosuran hydrochloride can improves pancreatic and renal function in diabetic rats .

HY-10655R

Palosuran (Standard) ACT-058362 (Standard)	Reference Standards Urotensin Receptor	Cardiovascular Disease
Palosuran (Standard) is the analytical standard of Palosuran. This product is intended for research and analytical applications. Palosuran (ACT-058362) is a potent, selective, and orally active antagonist of urotensin II receptor, with an IC50 of 3.6 nM for CHO cell membranes expressing human recombinant receptors. Palosuran can improves pancreatic and renal function in diabetic rats .

HY-P1318

Ac-RYYRIK-NH2	Opioid Receptor	Neurological Disease
Ac-RYYRIK-NH2 is a potent and partial agonist on ORL1 transfected in CHO cells (K_d=1.5 nM) and behaves as a endogenous ligand of ORL1. Ac-RYYRIK-NH2 is a specific antagonist for the activation of G protein and competitively antagonizes the stimulation of [ ³⁵S]-GTPgS binding to G proteins by nociceptin/orphanin FQ (noc/OFQ) in membranes and sections of rat brain .

HY-P1318A

Ac-RYYRIK-NH2 TFA	Opioid Receptor	Neurological Disease
Ac-RYYRIK-NH2 TFA is a potent and partial agonist on ORL1 transfected in CHO cells (K_d=1.5 nM) and behaves as a endogenous ligand of ORL1. Ac-RYYRIK-NH2 is a specific antagonist for the activation of G protein and competitively antagonizes the stimulation of [ ³⁵S]-GTPgS binding to G proteins by nociceptin/orphanin FQ (noc/OFQ) in membranes and sections of rat brain .

HY-130358

PDDHV	Calcium Channel	Neurological Disease
PDDHV is a calcium absorption inducer and may achieve 45Ca ²⁺ influx by stimulating vanillic acid receptor VR1. PDDHV induces 45Ca ²⁺ uptake (EC₅₀: 70 nM) in rat dorsal root ganglion neurons (expressing native vanilloid receptors) and calcium mobilization (EC₅₀: 125 nM) in VR1-transfected CHO cells. PDDHV also inhibits [3H]-resiniferatoxin (RTX) binding to the dorsal root ganglion membrane in rats .

HY-171328

RG-15	Dopamine Receptor	Neurological Disease
RG-15 is the orally active antagonist for dopamine receptor that exhibits goof affinity to human D2 receptor and human D3 receptor with pK_i of 8.23 and 10.49. RG-15 inhibits dopamine-stimulated [ ³⁵S]GTPγS binding with IC₅₀ of 21.2 nM (rat striatal membranes), 36.7 nM (mouse A9 cells expressing human D2L receptors) and 7.2 nM (CHO cells expressing human D3 receptors). RG-15 increases the turnover and biosynthesis of dopamine in mouse striatum and olfactory bulb, exhibiting antipsychotic activity .

HY-118945

FR191413	Prostaglandin Receptor Bradykinin Receptor	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
FR191413 is a selective bradykinin B2 receptor agonist that stimulates prostaglandin E2 production in WI-38 cells and activates BK B2 receptor-mediated pathways such as vasodilation and organ protection. FR191413 competitively binds to [ ³H]-BK in guinea pig ileum (GPI) membranes and CHO cells transfected with the human BK B2 receptor, with IC₅₀ values of 20.0 nM and 2.60 nM, respectively. FR191413 can be used in research related to cardiovascular diseases and diabetes, including hypertension, myocardial hypertrophy, myocardial infarction, arrhythmias, and diabetic nephropathy .

HY-182645

CRF1 receptor antagonist-2	CRFR	Neurological Disease
CRF1 receptor antagonist-2 is an orally active, blood-brain barrier permeable CRF1 receptor antagonist, with an IC₅₀ of 4 nM in CHO-K1 cell membranes and an IC₅₀ of 7 nM in rat brain cell membranes. CRF1 receptor antagonist-2 exerts anxiolytic effects in swim stress-loaded rats. CRF1 receptor antagonist-2 can be used in studies related to stress-induced anxiety .

HY-183599

MK-1088	Adenosine Receptor	Cancer
MK-1088 is an orally active A_2A/A_2B adenosine receptor antagonist with human A_2A K_i of 0.31 nM, human A_2B K_i 5.3 nM. MK-1088 blocks receptor downstream signaling, inhibits CREB phosphorylation and reverses adenosine-mediated immunosuppression. MK-1088 restores TNF−α release and enhances tumor immune surveillance. MK-1088 can be used for the research of cancer^[1].

HY-P992372

huAA98	Drug Derivative Transmembrane Glycoprotein	Cancer
huAA98 is a humanized monoclonal antibody and also a CD146 inhibitor. huAA98 binds to human CD146, regulates its activity and inhibits cancer-related angiogenesis, as well as tube formation, motility, proliferation and migration of endothelial cells. huAA98 inhibits angiogenesis in the chick chorioallantoic membrane assay and reduces microvessel density in human tumor xenograft models. huAA98 shows immunoreactivity only to neovascular vessels within tumors and inhibits the growth of tumor xenograft models. huAA98 can be used in studies related to cancer-related angiogenesis, liver cancer, leiomyosarcoma and pancreatic cancer .

HY-182714

N 0840 N6-Cyclopentyl-9-methyladenine	Adenosine Receptor	Cardiovascular Disease Neurological Disease
N 0840 is a neutral antagonist of adenosine A₁ receptor (A₁AR), with a K_i value of 279 nM in rats and 1185 nM in humans. N 0840 modulates adenosine A₁ receptor to increase forskolin-induced cyclic 3′,5′-adenosine monophosphate production, with a GTP shift value close to 1. N 0840 can be used in studies of neuroprotection, cardiovascular/renal function^[1].

HY-182440

AZD3783	5-HT Receptor	Neurological Disease
AZD3783 is an orally active, blood-brain barrier-penetrant 5-HT₁B receptor antagonist. AZD3783 reverses agonist-induced hypothermia, inhibits separation-induced vocalizations in guinea pig pups, and acts as a moderately permeable glycoprotein substrate with moderate clearance. AZD3783 inhibits hERG channel activity. AZD3783 is applicable for research on depression, anxiety disorders, and other psychiatric diseases associated with serotonergic neurotransmission .

HY-181649

S1R agonist 3	Sigma Receptor	Neurological Disease
S1R agonist 3 is a potent, selective and brain-penetrant sigma-1 receptor (S1R) agonist with a K_i of 1.5 nM. S1R agonist 3 reduces hyperlocomotion in wfs1abKO zebrafish larvae without affecting locomotion in wildtype wfs1abWT zebrafish larvae. S1R agonist 3 reverses Aβ_25-35 (HY-P0128)-induced learning and memory impairments. S1R ligand 1 can be used for the research of Alzheimer’s disease .

HY-181515

KOR agonist 8	Opioid Receptor	Neurological Disease
KOR agonist 8 (Compound 8a) is a κ-opioid receptor (KOR) agonist and an analgesic agent, with a K_i value of 5.3 nM for human KOR, and EC₅₀ values of 43.1 nM and 9236 nM for human KOR. It exhibits subtype selectivity for MOR/KOR and DOR/KOR. KOR agonist 8 is applicable for pain-related research .

HY-182421

GPR54 antagonist-1	Kisspeptin Receptor	Endocrinology Cancer
GPR54 antagonist‑1 is a GPR54 antagonist with IC₅₀ values of 3.6 nM and 15 nM against human and rat GPR54, respectively. GPR54 antagonist‑1 shows blood‑brain barrier penetration. GPR54 antagonist‑1 blocks the function of human and rat GPR54 receptors. GPR54 antagonist‑1 suppresses plasma luteinizing hormone levels in castrated male rats. GPR54 antagonist‑1 can be used for the study of prostate cancer and endometriosis .

HY-125790

Cyclazocine	Opioid Receptor	Neurological Disease
Cyclazocine is a μ, δ, and κ opioid receptor modulator with K_i values of 0.32, 1.1, and 0.18 nM, respectively. Cyclazocine exhibits "mixed" pharmacological activities, acting as a μ-partial antagonist, κ-agonist, and low-affinity δ ligand. Cyclazocine shows antinociceptive activity in mice. Cyclazocine can be used in studies on psychoactive substance addiction .

HY-N16471A

Escholtzine perchlorate	Cytochrome P450 5-HT Receptor	Neurological Disease
Escholtzine perchlorate is an Alkaloid. Escholtzine perchlorate can be isolated from Eschscholzia californica. Escholtzine perchlorate is a CYP3A4 inhibitor, 5-HT_1A receptor inhibitor with a CYP3A4 IC₅₀ of 13.4 μM, 5-HT_1A EC₅₀ of 11 μM. Escholtzine perchlorate can be used for the research of anxiety, depression .

HY-183773

KOR agonist-9	Opioid Receptor	Neurological Disease
KOR agonist-9 is a selective kappa opioid receptor (KOR) agonist with an EC₅₀of 1.41 nM. KOR agonist-9 exhibits >125-fold selectivity over μ/δ-opioid receptors. KOR agonist-9 antinociceptive and antipruritic effects in mice. KOR agonist-9 can be used for the research of pain, pruritus .

HY-N15339A

Convolamine hydrochloride	Sigma Receptor	Neurological Disease
Convolamine hydrochloride is a tropane alkaloid and a potent Sigma-1 receptor positive allosteric modulator with an IC₅₀ value of 289 nM. Convolamine hydrochloride can be extracted from Convolvulus plauricalis. Convolamine hydrochloride exhibits cognitive-improving and neuroprotective properties. Convolamine hydrochloride can be used in research related to Wolfram syndrome and Alzheimer's disease .

Cat. No.	Product Name	Type

HY-112624K

Dextran T5 (MW 5,000) Dextran 5; Dextran D5; Dextran T5(MW 4500-5500)	Biochemical Assay Reagents
Dextran T5 (MW 5,000) is a sulfated polysaccharide anti-apoptotic and autophagic agent. Dextran T5 (MW 5,000) has sulfated groups and interacts with cell membranes by mimicking endogenous glycosaminoglycans, inhibiting the mitochondrial apoptotic pathway and delaying DNA fragmentation to exert anti-apoptotic activity. Dextran T5 (MW 5,000) also promotes the conversion of LC3-I to LC3-II and the formation of autophagosomes to activate the autophagic pathway. Dextran T5 (MW 5,000) can prolong the survival cycle of CHO cells and increase the production of recombinant erythropoietin (EPO). The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong drug half-life, increase local concentration and reduce immune clearance activity. The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong the half-life of drugs, increase local concentrations, and reduce the activity of immune clearance .

Dextran T5 (MW 5,000)

Dextran 5; Dextran D5; Dextran T5(MW 4500-5500)

Biochemical Assay Reagents

Dextran T5 (MW 5,000) is a sulfated polysaccharide anti-apoptotic and autophagic agent. Dextran T5 (MW 5,000) has sulfated groups and interacts with cell membranes by mimicking endogenous glycosaminoglycans, inhibiting the mitochondrial apoptotic pathway and delaying DNA fragmentation to exert anti-apoptotic activity. Dextran T5 (MW 5,000) also promotes the conversion of LC3-I to LC3-II and the formation of autophagosomes to activate the autophagic pathway. Dextran T5 (MW 5,000) can prolong the survival cycle of CHO cells and increase the production of recombinant erythropoietin (EPO). The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong drug half-life, increase local concentration and reduce immune clearance activity. The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong the half-life of drugs, increase local concentrations, and reduce the activity of immune clearance .

Cat. No.	Product Name	Target	Research Area

HY-P1318

Ac-RYYRIK-NH2	Opioid Receptor	Neurological Disease
Ac-RYYRIK-NH2 is a potent and partial agonist on ORL1 transfected in CHO cells (K_d=1.5 nM) and behaves as a endogenous ligand of ORL1. Ac-RYYRIK-NH2 is a specific antagonist for the activation of G protein and competitively antagonizes the stimulation of [ ³⁵S]-GTPgS binding to G proteins by nociceptin/orphanin FQ (noc/OFQ) in membranes and sections of rat brain .

HY-P1318A

Ac-RYYRIK-NH2 TFA	Opioid Receptor	Neurological Disease
Ac-RYYRIK-NH2 TFA is a potent and partial agonist on ORL1 transfected in CHO cells (K_d=1.5 nM) and behaves as a endogenous ligand of ORL1. Ac-RYYRIK-NH2 is a specific antagonist for the activation of G protein and competitively antagonizes the stimulation of [ ³⁵S]-GTPgS binding to G proteins by nociceptin/orphanin FQ (noc/OFQ) in membranes and sections of rat brain .

Cat. No.	Product Name	Target	Research Area	Image

HY-P992372

huAA98	Drug Derivative Transmembrane Glycoprotein	Cancer
huAA98 is a humanized monoclonal antibody and also a CD146 inhibitor. huAA98 binds to human CD146, regulates its activity and inhibits cancer-related angiogenesis, as well as tube formation, motility, proliferation and migration of endothelial cells. huAA98 inhibits angiogenesis in the chick chorioallantoic membrane assay and reduces microvessel density in human tumor xenograft models. huAA98 shows immunoreactivity only to neovascular vessels within tumors and inhibits the growth of tumor xenograft models. huAA98 can be used in studies related to cancer-related angiogenesis, liver cancer, leiomyosarcoma and pancreatic cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N15339A

Convolamine hydrochloride	Structural Classification Alkaloids Microorganisms Tropane Alkaloids Source Classification	Sigma Receptor
Convolamine hydrochloride is a tropane alkaloid and a potent Sigma-1 receptor positive allosteric modulator with an IC₅₀ value of 289 nM. Convolamine hydrochloride can be extracted from Convolvulus plauricalis. Convolamine hydrochloride exhibits cognitive-improving and neuroprotective properties. Convolamine hydrochloride can be used in research related to Wolfram syndrome and Alzheimer's disease .

Cat. No.	Product Name		Classification

HY-W588725A

N3-Cho bromide 1 Publications Verification Azido-CHOline bromide		Azide
N3-Cho (Azido-choline) bromide is a click chemistry reagent containing an azide group that can be used in the synthesis of cell membrane structures .

Cat. No.	Product Name		Classification

HY-152656

2-Hydrazinyl-adenosine		Nucleoside Analogs Adenosine
2-Hydrazinyl-adenosine is a synthetic intermediate. Derivatives of 2-Hydrazinyl-adenosine act as A_2A adenosine receptor agonists. 2-Hydrazinyl-adenosine is used in the research of neurodegenerative diseases .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

CHO cell membranes

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Click Chemistry

Oligonucleotides

Natural
Products